Cure My Disease

Don't miss your cure!

 Log in / Sign up

New drug aritinercept aims to tame myasthenia gravis symptoms

NCT ID NCT07596901

Recruiting now Disease control Sponsor: Aurinia Pharmaceuticals Inc. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a new drug, aritinercept, in 81 adults with generalized myasthenia gravis. The drug works by blocking two immune signals (BAFF and APRIL) to reduce disease activity. Researchers are checking if it is safe and if it improves daily living activities compared to a placebo.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
aritinercept (a dual BAFF/APRIL inhibitor)
What this could lead to
If successful, this could lead to a new treatment option that helps control symptoms of generalized myasthenia gravis by targeting the immune system.
What could go wrong
This is an early Phase 1/2 trial with only 81 participants, so results are preliminary. The drug may not prove effective or could have side effects, and it is not a cure.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MYASTHENIA GRAVIS, GENERALIZED are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

myasthenia gravis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MYASTHENIA GRAVIS, GENERALIZED

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Aurinia Investigational Site

    RECRUITING

    Altamonte Springs, Florida, 32714, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Aurinia Investigational Site

    RECRUITING

    Boca Raton, Florida, 33487, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Aurinia Investigational Site

    RECRUITING

    Miami, Florida, 33173, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.